Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19786102 | 0.85 | HTR2A (0.49) | HTR2AHTR2CHSD17B10ALOX15MAPK1 | |
| SCHEMBL28060039 | 0.76 | HTR2A (0.51) | HTR2AHTR2CHSD17B10ALOX15MAPK1 | |
| SCHEMBL16299571 | 0.74 | HTR2A (0.41) | HTR2AHTR2CHSD17B10MAPK1KDM4E | |
| SCHEMBL26836970 | 0.71 | HTR2A (0.63) | HTR2AHTR2CHSD17B10ALOX15MAPK1 | |
| SCHEMBL21883969 | 0.70 | ABCB1 (0.45) | HTR2AHTR2CHSD17B10ALOX15MAPK1 | |
| SCHEMBL18669422 | 0.70 | GRIN2B (0.65) | PRCPHTR2AHTR2CCYP2D6GRIN2B | |
| SCHEMBL9880075 | 0.69 | HTR2A (0.40) | HTR2AHTR2CHSD17B10ALOX15MAPK1 | |
| SCHEMBL10686008 | 0.68 | HTR2C (0.56) | HTR2AHTR2CHSD17B10ALOX15MAPK1 | |
| SCHEMBL6644840 | 0.67 | HTR2A (0.44) | HTR2AHTR2CHSD17B10ALOX15MAPK1 | |
| SCHEMBL9880074 | 0.66 | HTR2A (0.40) | HTR2AHTR2CHSD17B10ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | PRCP 2582/4885HTR2A 4615/4885HTR2C 4566/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | PRCP 2373/4885HTR2A 4440/4885HTR2C 4453/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | PRCP 2373/4885HTR2A 4440/4885HTR2C 4453/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | PRCP 1784/4885HTR2A 3307/4885HTR2C 1923/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | PRCP 2373/4885HTR2A 4440/4885HTR2C 4453/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | PRCP 2373/4885HTR2A 4440/4885HTR2C 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.